Contents

Search

casirivimab

Indications: - treatment of outpatients with COVID-19 >= 14 years of age >= 40 kg - especially adults >= 65 years with COVID-19 at risk for severe disease - prevention of COVID-19 in people with high-risk exposures [3] - casirivimab + imdevimab appears to be effective against B.1.351 variant from South Africa [4] * must be administered in combination with imdevimab Contraindications: - not authorized hospitalized patients or patients who require oxygen therapy for COVID-19 * may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation Dosage: - 1200 mg or 4000 mg once by intravenous infusion Mechanism of action: - monoclonal antibody specifically directed against the spike protein of SARS-CoV2

Interactions

drug adverse effects of pharmaceutical monoclonal antibodies

General

monoclonal antibody to spike glycoprotein of SARS-CoV2 (COVID-19)

References

  1. FDA News Release. Nov 21, 2020 Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19
  2. NIH COVID-19 Treatment Guidelimes. Dec 2, 2020 The COVID-19 Treatment Guidelines Panel's Statement on the Emergency Use Authorization of the Casirivimab Plus Imdevimab Combination for the Treatment of COVID-19. https://www.covid19treatmentguidelines.nih.gov/statement-on-casirivimab-plus-imdevimab-eua/
  3. Regeneron Pharmaceuticals. Jan 26, 2021 Regeneron Reports Positive Interim Data with REGEN-COV Antibody Cocktail used as Passive Vaccine to Prevent COVID-19. https://www.prnewswire.com/news-releases/regeneron-reports-positive-interim-data-with-regen-cov-antibody-cocktail-used-as-passive-vaccine-to-prevent-covid-19-301214619.html - Regeneron Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV (casirivimab with imdevimab). Investors & Media, April 12, 2021 https://investor.regeneron.com/news-releases/news-release-details/phase-3-prevention-trial-showed-81-reduced-risk-symptomatic-sars
  4. NIH COVID-19 Treatment Guidelimes. April 21, 2021 Anti-SARS-CoV-2 Monoclonal Antibodies. https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/

Component-of

casirivimab/imdevimab (REGEN-COV)